Lawrence J. Ouellet

Lawrence J. Ouellet

Auto-generated profile, based on publicly available information

Lawrence J. Ouellet

Division of Epidemiology and Biostatistics/COIP (MC 923), School of Public Health, University of Illinois Chicago, 1603 W. Taylor, Chicago, IL 60607, USA

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
RBRebecca S Bolinski
Rebecca S Bolinski
SWSuzan Walters
Suzan Walters
ESElizabeth Salisbury-Afshar
Elizabeth Salisbury-Afshar
LOLawrence J. Ouellet
Lawrence J. Ouellet
Wiley JenkinsWiley Jenkins
Wiley Jenkins
MPMai T. Pho
Mai T. Pho
Background: The COVID-19 pandemic has worsened the opioid overdose crisis in the US. Rural communities have been disproportionately affected by opioid use and people who use drugs in these settings may be acutely vulnerable to pandemic-related disruptions due to high rates of poverty, social isolation, and pervasive resource limitations. Methods: We performed a mixed-methods study to assess the impact of the pandemic in a convenience sample of people who use drugs in rural Illinois. We conducted 50 surveys capturing demographics, drug availability, drug use, sharing practices, and mental health symptoms. In total, 19 qualitative interviews were performed to further explore COVID-19 knowledge, impact on personal and community life, drug acquisition and use, overdose, and protective substance use adaptations. Results: Drug use increased during the pandemic, including the use of fentanyl products such as gel encapsulated “beans” and “buttons”. Disruptions in supply, including the decreased availability of heroin, increased methamphetamine costs and a concomitant rise in local methamphetamine production, and possible fentanyl contamination of methamphetamine was reported. Participants reported increased drug use alone, experience and/or witness of overdose, depression, anxiety, and loneliness. Consistent access to harm reduction services, including naloxone and fentanyl test strips, was highlighted as a source of hope and community resiliency. Conclusions: The COVID-19 pandemic period was characterized by changing drug availability, increased overdose risk, and other drug-related harms faced by people who use drugs in rural areas. Our findings emphasize the importance of ensuring access to harm reduction services, including overdose prevention and drug checking for this vulnerable population.

16 May 2017 in Substance Abuse Treatment, Prevention, and Policy
Verified
Journal Article
Open access
PDF file
RCRedonna Chandler
Redonna Chandler
MGMichael S. Gordon
Michael S. Gordon
BKBridget Kruszka
Bridget Kruszka
LSLauren N. Strand
Lauren N. Strand
FAFrederick L. Altice
Frederick L. Altice
HCHeidi M Crane
Heidi M Crane
The STTR treatment cascade provides a framework for research aimed at improving the delivery of services, care and outcomes of PLWH. The development of effective approaches to increase HIV diagnoses and engage PLWH in subsequent steps of the treatment cascade could lead to earlier and sustained ART treatment resulting in viral suppression. There is an unmet need for research applying the treatment cascade to improve outcomes for those with criminal justice involvement. The Seek, Test, Treat, and Retain (STTR) criminal justice (CJ) cohort combines data from 11 studies across the HIV treatment cascade that focused on persons involved in the criminal justice system, often but not exclusively for reasons related to substance use. The studies were conducted in a variety of CJ settings and collected information across 11 pre-selected domains: demographic characteristics, CJ involvement, HIV risk behaviors, HIV and/or Hepatitis C infections, laboratory measures of CD4 T-cell count (CD4) and HIV RNA viral load (VL), mental illness, health related quality of life (QoL), socioeconomic status, health care access, substance use, and social support. The STTR CJ cohort includes data on 11,070 individuals with and without HIV infection who range in age from 18 to 77 years, with a median age at baseline of 37 years. The cohort reflects racial, ethnic and gender distributions in the U.S. CJ system, and 64% of participants are African-American, 12% are Hispanic and 83% are men. Cohort members reported a wide range of HIV risk behaviors including history of injection drug use and, among those who reported on pre-incarceration sexual behaviors, the prevalence of unprotected sexual intercourse ranged across studies from 4% to 79%. Across all studies, 53% percent of the STTR CJ cohort reported recent polysubstance use. The STTR CJ cohort is comprised of participants from a wide range of CJ settings including jail, prison, and community supervision who report considerable diversity in their characteristics and behavioral practices. We have developed harmonized measures, where feasible, to improve the integration of these studies together to answer questions that cannot otherwise be addressed.

1 September 2004 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
LOLawrence Ouellet
Lawrence Ouellet
DHDezheng Huo
Dezheng Huo
SBSusan L Bailey
Susan L Bailey
To assess associations between needle exchange program (NEP) use and drug injection risk practices. Between 1997–2000, injecting drug users (IDUs) in Chicago were recruited from NEPs and an area with no NEP, interviewed about risk practices, and counseled and tested for HIV. The risk practices of “regular NEP users” —those who obtained at least half of their needles from an NEP (n = 558) —were compared with those of IDUs who did not use an NEP (n = 175). In multivariate analysis, regular NEP users, compared with NEP nonusers, were less likely to receptively share needles (adjusted odds ratio [AOR], 0.30; 95% CI, 0.19–0.46); lend used needles (AOR, 0.47; 95% CI, 0.31–0.71); share cookers (AOR, 0.39; 95% CI, 0.25–0.61), cottons (AOR, 0.48; 95% CI, 0.32–0.72), or water (AOR, 0.41; 95% CI, 0.27–0.63); or use a needle for >1 injection (0.15; 95% CI, 0.08–0.27). Among those who shared needles, regular NEP users were significantly more likely to do so for a smaller proportion of injections, with fewer partners and persons socially closer, and to have always bleached used needles before injecting. Regular NEP use is associated with less frequent and lower risk HIV injection risk practices.

19 June 2009 in Journal of Urban Health
Verified
Journal Article
Closed access
PDF file
YYYoosik Youm
Yoosik Youm
MMMary Ellen Mackesy-Amiti
Mary Ellen Mackesy-Amiti
CWChyvette T. Williams
Chyvette T. Williams
LOLawrence J. Ouellet
Lawrence J. Ouellet

30 June 2008 in International Journal of Drug Policy
Verified
Journal Article
Closed access
LOLawrence J. Ouellet
Lawrence J. Ouellet

1 December 2000 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
LOLawrence J. Ouellet
Lawrence J. Ouellet
LTLorna E. Thorpe
Lorna E. Thorpe
DHDeZheng Huo
DeZheng Huo
SBSusan L. Bailey
Susan L. Bailey
AJAntonio D. Jimenez
Antonio D. Jimenez
EMEdgar Monterroso
Edgar Monterroso
To assess HIV prevalence, incidence, and associated risk factors among IDUs in Chicago. Seven hundred ninety-four street-recruited IDUs ranging in age from 18 to 50 years, who were not in drug treatment at study enrollment, were interviewed and tested for HIV at baseline and at two follow-ups scheduled 6 and 12 months after baseline. Questionnaires assessed respondents' demographic characteristics, medical and drug treatment histories, drug use, and sexual practices. HIV seroprevalence at baseline was 18%. Logistic regression identified the following determinants of prevalent HIV infection: Puerto Rican ethnicity, homosexual or bisexual self-identification, injecting for 4 or more years, and having smoked crack cocaine in the past 6 months. Follow-up data were collected from 584 (73.6%) participants. Mean duration of follow-up was 16.5 months, indicating that most subjects had follow-up intervals longer than the scheduled 6 and 12 months. Seven HIV seroconversions were observed in 632 person years of risk, yielding an incidence rate of 1.1 per 100 person years of risk. Injection for 3 or less years was positively associated with HIV seroconversion. The findings provide evidence of a decline in HIV incidence among IDUs, though newer injectors remain at elevated risk for infection.